title: Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
abstract: A dengue vaccine must induce protective immunity against the four serotypes of the virus. Our group has developed chimeric proteins consisting of the protein P64k from Neisseria meningitidis and the domain III from the four viral envelope proteins. In this study, the immunogenicity of a tetravalent vaccine formulation using aluminum hydroxide as adjuvant was evaluated in mice. After three doses, neutralizing antibody titers were detected against the four viral serotypes, the lowest seroconversion rate being against dengue virus serotype 4. One month after the last dose, immunized animals were challenged with infective virus, and partial but statistically significant protection was found to have been achieved. Based on these results, further studies in mice and non-human primates using this tetravalent formulation in a prime-boost strategy with attenuated viruses are strongly recommended.
authors.affiliation: Vaccines Division, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Playa, Havana, 11 600, Cuba.
authors.forename: Laura
authors.initials: L
authors.lastname: Lazo
authors.forename: Alienys
authors.initials: A
authors.lastname: Izquierdo
authors.forename: Edith
authors.initials: E
authors.lastname: Suzarte
authors.forename: Lázaro
authors.initials: L
authors.lastname: Gil
authors.forename: Iris
authors.initials: I
authors.lastname: Valdés
authors.forename: Ernesto
authors.initials: E
authors.lastname: Marcos
authors.forename: Mayling
authors.initials: M
authors.lastname: Álvarez
authors.forename: Yaremis
authors.initials: Y
authors.lastname: Romero
authors.forename: María Guadalupe
authors.initials: MG
authors.lastname: Guzmán
authors.forename: Gerardo
authors.initials: G
authors.lastname: Guillén
authors.forename: Lisset
authors.initials: L
authors.lastname: Hermida Cruz
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000536:Aluminum Hydroxide / Q000008:administration & dosage; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage; D003715:Dengue / Q000276:immunology / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D003716:Dengue Virus / Q000276:immunology*; D004195:Disease Models, Animal; D005260:Female; D008807:Mice, Inbred BALB C; D016019:Survival Analysis; D014611:Vaccination / Q000379:methods; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D001425:Bacterial Outer Membrane Proteins; D053059:Dengue Vaccines; D022223:Vaccines, Subunit; C112623:lpdA protein, Neisseria meningitidis; D000536:Aluminum Hydroxide
keywords: dengue; domain III; vaccine; virus